Briefing: STAT+: Six drugmakers, six months: Charting the FDA’s course in the post-Prasad era

Strategic angle: Will the FDA’s regulatory policies, particularly for rare-disease drugs, shift in the wake of Vinay Prasad’s imminent departure?